Live from ASCO 2021 | Ascentage Pharma Presents Updated Results of MDM2-p53 Inhibitor Alrizomadlin (APG-115) Demonstrating an ORR of 24.1% Including Complete Response in Combination with Pembrolizumab in Patients with Advanced Melanoma Resistant or Refractory to Prior Immuno-Oncologic Drugs

SUZHOU, China, and ROCKVILLE, Md., June 8, 2021 /PRNewswire/ — Ascentage Pharma (6855.HK), a globally focused, clinical-stage…

TIAN RUIXIANG Holdings Ltd Announces Initial Closing of Follow-on Public Offering

BEIJING, June 8, 2021 /PRNewswire/ — TIAN RUIXIANG Holdings Ltd (Nasdaq: TIRX) (the "Company"), a China-based insurance…

Intento Named a 2021 Cool Vendor by Gartner

Intento is recognized as a 2021 Gartner Cool Vendor for Conversational and Natural Language Technologies SAN…

Bitnine provides Graph DB to Nordic tech company

SAN FRANCISCO, June 8, 2021 /PRNewswire/ — Bitnine (CEO Cheol Sun Kang) announced that the agreement…